ArticleBlood advances2019

Myeloid translocation gene CBFA2T3 directs a relapse gene program and determines patient-specific outcomes in AML.

Nickolas Steinauer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.